Marketing for clinical trial software companies and CROsTrial teams test a system before they trust it. We publish the evidence guides they use.

A clinical operations lead comparing EDC, eTMF or RTSM vendors wants to know what an inspector will ask of the system, what a new guideline changes in a study build, and how to test a vendor before signing. VayoMed researches and publishes those answers for you, and runs the website, press releases and LinkedIn around them, as one annual subscription.

$24K/year. Website, research, press releases, LinkedIn, domains and AI visibility.

What trial teams asked to see

100%of demo requests came with a company name and a phone number

  • The whole platform30%
  • EDC30%
  • CTMS20%
  • eCOA10%
  • Scales, linguistic validation and rater training10%
50%
found the site through a search engine
10%
had a recorded ChatGPT referral
30%
were site coordinators; the rest clinical operations, data and medical affairs

Demo requests to a clinical trial software company, September and October 2026. Name withheld. Shares of the demo requests received, counted on November 17, 2026, after removing test submissions.

17
linked sources in the average research report for a client
6,100
words in the average report
283
clicks from the average press release to its website
How trial teams choose a system

Six questions a trial team settles before the demo. Each one is something you can publish.

The demo requests our client received came from site coordinators, clinical operations, data management and medical affairs. These are the questions those people work through first.

  1. 01Will it stand up in an inspection?

    What they look for

    How the system handles audit trails, electronic signatures and certified copies under 21 CFR Part 11 and ICH E6(R3).

    What we build

    Reports built from FDA inspection findings and warning letters on what inspectors ask of computerized systems, and a trust page that states what you hold.

  2. 02Which modules do we actually need?

    What they look for

    A plain account of EDC, CTMS, eTMF, RTSM and eCOA, and which of them a trial of their size requires.

    What we build

    A platform page and a page for each module, and a module map for small sponsors derived from registry data.

  3. 03How do we test it before we sign?

    What they look for

    Checks they can run themselves in a demo or during user acceptance testing.

    What we build

    Acceptance scripts published as reports: how to test inspection readiness in a vendor demo, or the handoff between sponsor and CRO systems.

  4. 04Does it handle our kind of trial?

    What they look for

    Their own design: oncology with central review, CNS trials with rater training, decentralised elements, device investigations, sites in several regions.

    What we build

    A report for each trial type you want to be chosen for, built from the registries and the guidance that governs it.

  5. 05What changed in the rules this year?

    What they look for

    ICH E6(R3), the ICH M11 protocol template, new FDA guidance, EU results disclosure. They want to know what it means for a study build.

    What we build

    A report every week and a press release every month on each change and what it requires of the systems.

  6. 06Can we rely on the AI functions?

    What they look for

    How an AI function was qualified, for which use, and what the audit trail records.

    What we build

    A qualification guide for AI functions in clinical trial software, and a weekly reading of how AI assistants describe your product.

Claims

Nobody issues a “Part 11 certificate”. So we write what the system does, and link the rule.

An inspector asks the sponsor how a system was validated, not the vendor for a badge. Buyers know this, and a claim they cannot check counts against you. Every statement we publish for you names the requirement and links its source.

“Part 11 certified”

What buyers usually see

A badge on the home page. No authority issues one, and the buyer's quality team knows it.

With VayoMed

Each requirement stated beside the function that supports it, with the regulation linked.

Speed claims with no source

What buyers usually see

“Database lock 40% faster”, with nothing a buyer can verify.

With VayoMed

Figures come from public registries and inspection data, with the source linked, or they are left out.

Sponsor logos as proof

What buyers usually see

A wall of sponsor names, some of whom never agreed to be listed.

With VayoMed

Evidence by trial type and phase. No sponsor of yours is named.

Evidence

Research built from the records trial teams work under. Not from a feature list.

We publish long, sourced reports on the questions your buyers are evaluating. For a clinical trial software client those reports are built from public records like these, and every source is linked.

17
linked sources in the average report
6,100
words in the average report
3
charts in the average report
  • ClinicalTrials.gov and the EU trial registry

    How trials are actually designed: endpoints, countries, instruments, and what must be disclosed.

  • FDA inspection data and warning letters

    What inspectors cite about records, monitoring and computerized systems.

  • ICH guidelines

    What E6(R3), M11 and the other guidelines require of a study build.

  • 21 CFR Part 11 and Part 312

    The record-keeping and electronic-records rules a system has to support.

  • FDA and EMA guidance

    What a new guidance changes, and from when.

  • CDISC standards

    How instruments and outcomes map to the data a system has to deliver.

  • National rules for trial data

    What changes when a trial runs sites in several regions.

  • Published studies

    The evidence behind a design choice, such as central review or rater training.

What a report for a trial-software company looks like

Each of these is a kind of report we have published for a client.

Reports average about 6,100 words and 17 linked sources.

  • An acceptance script a sponsor can run in a vendor demo to test inspection readiness
  • A module map for small sponsors: how many systems a first trial needs, derived from registry data
  • What inspection findings and warning letters ask of computerized systems
  • What a new guideline changes in a study build, field by field
  • A reconciliation check for the handoff between sponsor and CRO systems
  • How to qualify AI functions in clinical trial software
What we build and run

Six things a trial team can check. One team behind all of them.

Everything below is included in the subscription. We do the work. You decide how much you review: approve each piece before it goes out, or read it once it is live.

Built once, run every day

A website organised by module

Built or rebuilt around your platform, with a page for each module and each solution, a trust page and a demo request form. Hosting, updates and analytics stay with us.

How the website works

Every week

Sourced research reports

Long reports on the questions sponsors, CROs and sites are evaluating, built from registries, inspection data and guidance, and published on your site.

How research works

Every month

A press release on PR Newswire

Written from the research and distributed. Each of our last 11 releases was published by 274 to 311 news sites.

How PR works

Planned two weeks ahead

A LinkedIn page worth following

Posts made from your research and your product, so clinical operations and data managers see something useful, not a product advert.

How LinkedIn works

Every Monday

A reading of AI answers

How AI assistants answer your buyers' questions: where you are named, where competitors are, and which sources were cited. One in ten of a client's demo requests had a recorded ChatGPT referral.

How tracking works

As they arrive

Demo requests with context

The form asks for the role and the module of interest. Each request arrives in your workspace with its recorded source and the pages the visitor read, when those were recorded.

See the workspace
Results so far

What a trial-software client has received. Name withheld, numbers real.

Read from our own lead records, publishing records and distribution reports on November 17, 2026. The client joined in August 2026.

100%
of demo requests came with a company name and a phone number
297
news sites published its average press release
283
clicks from the average release to its website
17
linked sources in the average research report
Your options

How this compares with what trial-technology companies usually try.

What a buyer finds before the demo

Conferences and booths
A brochure
A product marketing hire
Feature pages
A general B2B agency
Campaign pages
VayoMed
Sourced research on the questions they are evaluating

Regulatory accuracy

Conferences and booths
Not applicable
A product marketing hire
Depends on the hire
A general B2B agency
Generalist writers; your team rewrites
VayoMed
Built from regulations, guidance and inspection data, with every source linked

Output

Conferences and booths
A few events a year
A product marketing hire
What one person can write
A general B2B agency
Per campaign
VayoMed
A report every week and a release every month

Work left for your team

Conferences and booths
Travel and follow-up
A product marketing hire
Managing the hire
A general B2B agency
Briefing and correcting
VayoMed
Review as much as you choose

Price

Conferences and booths
Per event
A product marketing hire
A salary
A general B2B agency
Monthly retainer or project fee
VayoMed
$24K a year, fixed
The first 90 days

What happens after you sign.

The order is fixed; the dates depend on how quickly material and reviews come back.

  1. 01Weeks 1–2

    The product record

    We write down your modules, the requirement each function supports, the trial types you serve and the claims to avoid. We take the first AI-visibility reading and open your workspace.

  2. 02Month 1

    First output

    The first research report is written and the first press release is drafted. Your LinkedIn page is reworked and the first two-week plan is made.

  3. 03Months 1–2

    Website

    The site is built or rebuilt around your platform and modules and launched on your domain, with the demo form and analytics live.

  4. 04Month 3 onwards

    Rhythm

    A report every week, a release every month, LinkedIn on a two-week plan, AI visibility every Monday, and a summary every quarter.

Price

One subscription. Everything on this page.

This is not software your team has to run. We build the website, publish the research, send the releases, manage LinkedIn and report the results. You see and steer all of it in your client workspace.

Included

  • Website: build, hosting and operations
  • Research reports and articles, published on your site
  • One press release a month on PR Newswire
  • LinkedIn company page and content
  • Domain portfolio management
  • AI visibility tracking

Priced separately

Premium placement in named business and technology outlets: from $2,000 per placement.

Done-for-You annual subscription

$24K/ year

12-month agreement. Equivalent to $2,000 per month; monthly billing or annual prepayment, as agreed.

The comparable traditional route is estimated at $200–300K+ a year across writers, PR agencies and wire distribution.

Fit

Who this works for, and who should look elsewhere.

A strong fit

  • You sell clinical trial software or trial services to sponsors, CROs or sites.
  • Your buyers decide on compliance and evidence, and take months to choose.
  • One person on your team can review a report within a few days.
  • You can commit for a year. Search and AI visibility build over months, not weeks.

A better fit elsewhere

  • You want validation documents, SOPs or a quality system written. We do marketing, not validation.
  • You want a claim such as “FDA approved software” or “Part 11 certified”. We will not write it.
  • You want demo requests bought through advertising. We do not run ads.
  • You want a website only. The site is one part of the subscription and is not sold alone.
FAQ

Common questions from trial-technology companies.

Can you write accurately about GCP and Part 11?

We write from the regulation, the guidance and public inspection and registry data, and link every source so your team can check a claim in a minute. For our client the reports cite ICH guidelines, FDA and EMA guidance, FDA inspection data, ClinicalTrials.gov and the EU trial registry.

What kinds of inquiry should we expect?

Every demo request a client received in September and October 2026 came with a company name and a phone number. 30% asked for the whole platform, 30% for EDC, 20% for CTMS, 10% for eCOA and 10% for scale management and rater training, from site coordinators, clinical operations, data management and medical affairs. We do not promise a number.

Will you name our sponsors?

No. We show what the system is for by trial type and phase. A sponsor is named only if you give us a public reference to use.

Our buyers are specialists. Will they read this?

They are who the reports are written for. Each one answers a working question, such as how to test inspection readiness in a demo, and gives the reader something to use: a script, a checklist or a table drawn from the public record.

Which market do you track for AI visibility?

The United States by default: we read how AI assistants answer your buyers' questions there every week.

What do you need from us?

Product documentation, the list of modules and the requirements they support, brand files and screenshots. After onboarding, a reviewer who answers within a few days.

How much does it cost?

$24,000 a year for everything on this page, on a 12-month agreement, billed monthly or prepaid annually as agreed.

Next step

See what a buyer is told today. Then talk to us about what they should be told.

The free report is a snapshot of your domain: search rankings, estimated search traffic and where the web mentions you. Enter your domain, confirm your email, and we email you the link.

$24K/year. One annual subscription. Six services. Fully managed.
Monthly billing or annual prepayment, as agreed.